The Eigth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT VII, took place in
Sitges, Barcelona from the 10th to 14th September, 2006. Basic scientists, clinical …

Despite the introduction of many second-generation antiepileptic drugs (AEDs) in the past
15 years, a third of patients with epilepsy remain refractory to available treatments, and …

Purpose: To study the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive
therapy for refractory partial seizures in adults with≥ 4 partial‐onset seizures (simple or …

This review briefly summarizes the information on the molecular mechanisms of action,
pharmacokinetic profiles and drug interactions of novel (third-generation) antiepileptic …

OBJECTIVE: To investigate the efficacy and safety of once-daily eslicarbazepine acetate
(ESL) when used as add-on treatment in adults with≥ 4 partial-onset seizures per 4-week …

Eslicarbazepine acetate (ESL) is a novel once‐daily antiepileptic drug (AED) approved in
Europe since 2009 that was found to be efficacious and well tolerated in a phase III clinical …

Objectives–To evaluate the efficacy and safety of eslicarbazepine acetate (ESL) as
adjunctive therapy in adults with partial‐onset seizures. Material and methods–Double …

Although adjunctive treatment with modern antiepileptic drugs (AEDs) is standard care in
refractory epilepsy, it is unclear how much of the effect can be attributed directly to the AEDs …

Background Adjunctive newer antiseizure medications (ASMs) are being used in patients
with treatment-resistant focal-onset seizures (FOS). An updated network meta-analysis …

Stefan H. Epilepsy in the elderly: facts and challenges. Acta Neurol Scand: 2011: 124: 223–
237.© 2010 John Wiley & Sons A/S. The incidence of epilepsy in the elderly has increased …